title: Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
authors.affiliation: University Hospital, Department of Internal Medicine II (Haematology, Oncology, Immunology, Rheumatology), Tübingen, Germany.
authors.forename: Ina
authors.initials: I
authors.lastname: Kötter
authors.forename: Manfred
authors.initials: M
authors.lastname: Zierhut
authors.forename: Anja
authors.initials: A
authors.lastname: Eckstein
authors.forename: Reinhard
authors.initials: R
authors.lastname: Vonthein
authors.forename: Thomas
authors.initials: T
authors.lastname: Ness
authors.forename: Ilhan
authors.initials: I
authors.lastname: Günaydin
authors.forename: Bodo
authors.initials: B
authors.lastname: Grimbacher
authors.forename: Sabine
authors.initials: S
authors.lastname: Blaschke
authors.forename: Hans-Hartmut
authors.initials: HH
authors.lastname: Peter
authors.forename: Lothar
authors.initials: L
authors.lastname: Kanz
authors.forename: Nicole
authors.initials: N
authors.lastname: Stübiger
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D031300:Retinal Vasculitis / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D014606:Uveitis, Anterior / Q000188:drug therapy* / Q000209:etiology; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000209:etiology; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins